J B Chemicals &

Which are the latest news on J B Chemicals &?

Why is J B Chemicals & Pharmaceuticals Ltd falling/rising?

As of 23-Jun, J B Chemicals & Pharmaceuticals Ltd's stock price has risen to Rs 2,234.80, reflecting a 1.2% increase, driven by strong historical performance and positive technical indicators. The stock has significantly outperformed the Sensex and shows solid fundamentals, including high institutional holdings and efficient management.

As of 23-Jun, J B Chemicals & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 2,234.80, reflecting an increase of Rs 26.5 or 1.2%. This upward movement can be attributed to several factors highlighted in the recent performance data. <BR><BR>The stock has shown strong performance over various time periods, with a year-to-date increase of 22.76%, significantly outperforming the Sensex, which has declined by 10.58% during the same timeframe. Over the past year, the stock has risen by 24.34%, while the broader market has faced a decline of 6.96%. Additionally, the stock has demonstrated impressive growth over the last three years, with a return of 93.61%, compared to the Sensex's 20.99%.<BR><BR>Today, the stock is trading close to its 52-week high, being only 3.16% away from Rs 2,299.95. It has also been gaining consistently, with a rise of 1.83% over the last two days. The stock reached an intraday high of Rs 2,260, which is a 2.34% increase. Furthermore, J B Chemicals & Pharmaceuticals Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Despite a decrease in investor participation, as evidenced by a 37.81% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading, with a value of Rs 1.03 crore based on 2% of the 5-day average traded value. The company's high management efficiency, reflected in a return on equity (ROE) of 18.05%, and a low debt-to-equity ratio of 0.02 times, further bolster investor confidence. Additionally, the high institutional holdings at 37.72% suggest that knowledgeable investors are backing the stock, which can positively influence its price movement.<BR><BR>In summary, the combination of strong historical performance, positive technical indicators, and solid fundamentals contributes to the rising stock price of J B Chemicals & Pharmaceuticals Ltd.

How big is J B Chemicals &?

As of 10th June, J B Chemicals & Pharmaceuticals Ltd has a market capitalization of 35,628.00 Cr, with recent Net Sales of 4,147.79 Cr and a Net Profit of 709.46 Cr. Shareholder's Funds are 4,159.22 Cr and Total Assets are 4,961.77 Cr.

As of 10th June, J B Chemicals & Pharmaceuticals Ltd has a market capitalization of 35,628.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 4,147.79 Cr and a Net Profit of 709.46 Cr.<BR><BR>For the latest annual period ending March 2026, Shareholder's Funds amounted to 4,159.22 Cr, while Total Assets were reported at 4,961.77 Cr.

Who are in the management team of J B Chemicals &?

The management team of J B Chemicals & includes Ranjit Shahani (Chairman), Nikhil Chopra (CEO), Padmini Khare Kaicker, Sumit Bose (both Independent Directors), Prashant Kumar, Gaurav Trehan (both Non-Independent Directors), and Sandeep Phadnis (Company Secretary). They are responsible for the company's strategic direction and regulatory compliance.

The management team of J B Chemicals & includes the following individuals:<BR><BR>1. **Ranjit Shahani** - Chairman & Independent Director<BR>2. **Nikhil Chopra** - Whole Time Director & CEO<BR>3. **Padmini Khare Kaicker** - Non-Executive & Independent Director<BR>4. **Sumit Bose** - Non-Executive & Independent Director<BR>5. **Prashant Kumar** - Non-Executive & Non-Independent Director<BR>6. **Gaurav Trehan** - Non-Executive & Non-Independent Director<BR>7. **Sandeep Phadnis** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the J B Chemicals &?

J B Chemicals & peers include Anthem Bioscienc, Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, Emcure Pharma, Wockhardt, Acutaas Chemical, and Sai Life. J B Chemicals & has a 1-year return of 31.30%, with average growth and good management risk compared to its peers.

Peers: The peers of J B Chemicals & are Anthem Bioscienc, Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, Emcure Pharma, Wockhardt, Acutaas Chemical, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Glaxosmi. Pharma, while Good management risk is found at Anthem Bioscienc, Ipca Labs, Gland Pharma, J B Chemicals &, and Emcure Pharma. Average management risk is noted at Wockhardt and Sai Life. Growth is Excellent at Anthem Bioscienc and Acutaas Chemical, while Below Average growth is seen at Ipca Labs, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, and J B Chemicals &. Good growth is reported at Emcure Pharma, while Average growth is noted at Wockhardt. Capital Structure is Excellent for Anthem Bioscienc, Gland Pharma, Ajanta Pharma, Glaxosmi. Pharma, J B Chemicals &, Acutaas Chemical, and Sai Life, while Good capital structure is found at Emcure Pharma, and Below Average at Wockhardt.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 186.21%, while Glaxosmi. Pharma has the lowest at -36.01%. J B Chemicals & has a 1-year return of 31.30%, which is significantly higher than Glaxosmi. Pharma but lower than Acutaas Chemical. Additionally, Wockhardt and Piramal Pharma have negative six-month returns.

What does J B Chemicals & do?

J B Chemicals & Pharmaceuticals Ltd manufactures and markets pharmaceutical formulations, herbal remedies, and Active Pharmaceutical Ingredients (APIs). As of March 2026, it reported net sales of ₹904 Cr and a net profit of ₹101 Cr, with a market cap of ₹35,628 Cr.

Overview: <BR>J B Chemicals & Pharmaceuticals Ltd is engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations, herbal remedies, and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History: <BR>The company was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals on December 18, 1976. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 904 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 101 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 35,628 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 48.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.30% <BR>Debt Equity: -0.21 <BR>Return on Equity: 17.55% <BR>Price to Book: 8.52 <BR><BR>Contact Details: <BR>Address: Neelam Centre 4th Floor, B-Wing Hind Cycle Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-2482 2222/2493 0918 <BR>Email: investorelations@jbcpl.com <BR>Website: http://www.jbpharma.com

Are J B Chemicals & Pharmaceuticals Ltd latest results good or bad?

J B Chemicals & Pharmaceuticals Ltd's latest Q4 FY26 results are concerning, with a net profit decline of 48.77% quarter-on-quarter and a 15.07% drop in net sales. Despite solid full-year growth for FY25, the sharp downturn in Q4 raises significant challenges for the company.

The latest results for J B Chemicals & Pharmaceuticals Ltd indicate a concerning performance in Q4 FY26. The company reported a net profit of ₹101.37 crore, which represents a significant decline of 48.77% quarter-on-quarter and 30.42% year-on-year. Similarly, net sales fell to ₹904.23 crore, down 15.07% from the previous quarter and 4.77% compared to the same quarter last year.<BR><BR>Additionally, the operating margin, excluding other income, decreased sharply to 22.24%, marking the lowest level for FY26 and a contraction of 558 basis points from the previous quarter. This decline in profitability and sales raises questions about the company's operational efficiency and pricing power.<BR><BR>While the full-year results for FY25 showed solid growth, with a 12.40% increase in net sales and a 19.38% rise in net profit, the sharp downturn in Q4 has overshadowed these achievements. Overall, the latest results suggest that J B Chemicals is facing significant challenges, making the current financial performance appear more negative than positive.

Should I buy, sell or hold J B Chemicals & Pharmaceuticals Ltd?

When is the next results date for J B Chemicals & Pharmaceuticals Ltd?

The next results date for J B Chemicals & Pharmaceuticals Ltd is 11 May 2026.

The next results date for J B Chemicals & Pharmaceuticals Ltd is scheduled for 11 May 2026.

How has been the historical performance of J B Chemicals &?

J B Chemicals & has shown consistent growth in net sales and profitability, with net sales increasing from 1,643.20 Cr in Mar'19 to 3,917.99 Cr in Mar'25, and profit after tax rising from 193.97 Cr to 659.58 Cr during the same period. The company also improved its operational efficiency and maintained a solid balance sheet, with total assets growing significantly.

Answer:<BR>The historical performance of J B Chemicals & shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>J B Chemicals & has demonstrated significant growth in net sales, increasing from 1,643.20 Cr in Mar'19 to 3,917.99 Cr in Mar'25. This upward trajectory reflects a robust annual growth rate, particularly notable from Mar'24 to Mar'25, where sales rose from 3,484.18 Cr to 3,917.99 Cr. The total operating income followed a similar pattern, reaching 3,917.99 Cr in Mar'25. Operating profit, excluding other income, also improved significantly, rising from 305.39 Cr in Mar'19 to 1,031.84 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax increased from 286.99 Cr in Mar'19 to 887.39 Cr in Mar'25, while profit after tax surged from 193.97 Cr to 659.58 Cr in the same period. The company's total assets grew from 1,813.98 Cr in Mar'20 to 4,265.36 Cr in Mar'25, reflecting a solid asset base. Total liabilities increased from 1,813.98 Cr to 4,265.36 Cr, with a notable reduction in long-term borrowings to zero by Mar'25. Cash flow from operating activities improved significantly, reaching 902.00 Cr in Mar'25, contributing to a closing cash balance of 115.00 Cr. Overall, J B Chemicals & has shown a strong upward trend in both revenue and profitability, alongside a solid balance sheet position.

Is J B Chemicals & technically bullish or bearish?

As of November 7, 2025, J B Chemicals & shows a mildly bullish trend driven by daily moving averages, despite caution from weekly and monthly indicators like MACD and KST, while volatility remains low according to Bollinger Bands.

As of 7 November 2025, the technical trend for J B Chemicals & has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly and monthly MACD and KST readings are mildly bearish, suggesting some caution. The RSI shows no signals in both weekly and monthly time frames, and Bollinger Bands are sideways, indicating a lack of volatility. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages, despite the bearish signals from other indicators.

Who are the top shareholders of the J B Chemicals &?

The top shareholders of J B Chemicals & include Tau Investment Holdings Pte. Ltd. with 47.84%, followed by 31 mutual fund schemes at 16.26%, 258 foreign institutional investors at 18.3%, and the Kotak Emerging Equity Scheme as the largest public shareholder at 4.25%. Individual investors collectively own 13.28% of the company.

The top shareholders of J B Chemicals & include several key players. The majority shareholder is Tau Investment Holdings Pte. Ltd., which holds 47.84% of the company. In addition, the company has a significant presence of institutional investors, with 31 mutual fund schemes holding a combined 16.26% and 258 foreign institutional investors (FIIs) owning 18.3%. The highest public shareholder is the Kotak Emerging Equity Scheme, which holds 4.25%. Individual investors collectively own 13.28% of the company.

Is J B Chemicals & overvalued or undervalued?

As of November 27, 2020, J B Chemicals & is considered very expensive and overvalued with a PE Ratio of 40.03 and an EV to EBITDA of 25.18, significantly higher than peers like Sun Pharma and Cipla, despite a recent return of 10.28% that underperformed the Sensex's 3.84%.

As of 27 November 2020, the valuation grade for J B Chemicals & has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 40.03, an EV to EBITDA of 25.18, and a PEG Ratio of 2.12, all of which are notably high compared to its peers.<BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated as attractive, has a PE Ratio of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight that J B Chemicals & is trading at a premium relative to its peers. Additionally, while the stock has seen a return of 10.28% over the past month, it has underperformed the Sensex, which returned 3.84% in the same period, reinforcing the notion of overvaluation.

Has J B Chemicals & declared dividend?

J B Chemicals & Pharmaceuticals Ltd has declared an 850% dividend, amounting to ₹8.5 per share, with an ex-date of February 7, 2025. While recent short-term returns have been negative, the company has shown significant long-term growth, particularly with a total return of 404.05% over the past five years.

J B Chemicals & Pharmaceuticals Ltd has declared an 850% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 850%<BR>- Amount per share: 8.5<BR>- Ex-date: 07 Feb 2025<BR><BR>Dividend Yield: 0.9%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -2.78%, the dividend return was 0.48%, resulting in a total return of -2.3%.<BR><BR>For the 1-year period, the price return was -3.19%, the dividend return was 0.81%, leading to a total return of -2.38%.<BR><BR>Over the 2-year period, the price return was 61.46%, the dividend return was 2.56%, culminating in a total return of 64.02%.<BR><BR>In the 3-year period, the price return was 115.06%, the dividend return was 6.00%, resulting in a total return of 121.06%.<BR><BR>For the 4-year period, the price return was 126.48%, the dividend return was 7.68%, leading to a total return of 134.16%.<BR><BR>In the 5-year period, the price return was 383.78%, the dividend return was 20.27%, culminating in a total return of 404.05%.<BR><BR>Overall, J B Chemicals & Pharmaceuticals Ltd has declared a significant dividend, and while recent returns over shorter periods have been negative, the long-term performance shows substantial growth, particularly in price returns over the last five years.